Education
About Us
Working with TipRanks
Follow Us
Cartesian Therapeutics (RNAC)
NASDAQ:RNAC
RNAC Stock Chart & Stats
$7.22
-$0.34(-1.95%)
At close: 4:00 PM EST
$7.22
-$0.34(-1.95%)
Day’s Range― - ―
52-Week Range$5.98 - $20.30
Previous CloseN/A
Volume45.37K
Average Volume (3M)180.20K
Market Cap
$187.75M
Enterprise Value$134.97M
Total Cash (Recent Filing)$143.38M
Total Debt (Recent Filing)$12.60M
Price to Earnings (P/E)―
Beta2.27
Next Earnings
Mar 05, 2026EPS Estimate
-0.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.38
Shares Outstanding26,003,607
10 Day Avg. Volume274,035
30 Day Avg. Volume180,196
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)-68.21
Price to Sales (P/S)11.92
P/FCF Ratio-14.16
Enterprise Value/Market Cap0.72
Enterprise Value/Revenue123.71
Enterprise Value/Gross Profit-11.53
Enterprise Value/Ebitda-2.75
Forecast
1Y Price Target
$34.67Price Target Upside380.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-2.27
Revenue Forecast (FY)$1.97M
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe lead candidate Descartes-08 has shown deeper responses in a Phase 2 trial for myasthenia gravis than benchmarks for approved biologics, and a Phase 3 trial is currently enrolling.
Market PotentialThere is potential for significant growth if RNAC expands into other autoimmune indications, with trials already enrolling for lupus and a pediatric basket trial.
Safety And AccessibilityMRNA-based cell therapies present multiple safety advantages, allowing them to be given in an outpatient setting and in smaller community practices, increasing patient access.
Bears Say
Challenges In IndicationSLE/LN has proven to be a difficult indication for cell therapy due to limited fitting study patients.
Competition And Resource AllocationCartesian made the strategic decision to pause development in SLE as there is significant competition in the space.
Focus And Resource ManagementCartesian will not continue development of Descartes-08 in SLE, refocusing resources on MG and newly added myositis.
Cartesian Therapeutics News
RNAC FAQ
What was Cartesian Therapeutics’s price range in the past 12 months?
Cartesian Therapeutics lowest stock price was $5.98 and its highest was $20.30 in the past 12 months.
What is Cartesian Therapeutics’s market cap?
Cartesian Therapeutics’s market cap is $187.75M.
When is Cartesian Therapeutics’s upcoming earnings report date?
Cartesian Therapeutics’s upcoming earnings report date is Mar 05, 2026 which is in 72 days.
How were Cartesian Therapeutics’s earnings last quarter?
Cartesian Therapeutics released its earnings results on Nov 06, 2025. The company reported -$1.38 earnings per share for the quarter, missing the consensus estimate of -$0.847 by -$0.533.
Is Cartesian Therapeutics overvalued?
According to Wall Street analysts Cartesian Therapeutics’s price is currently Undervalued.
Does Cartesian Therapeutics pay dividends?
Cartesian Therapeutics does not currently pay dividends.
What is Cartesian Therapeutics’s EPS estimate?
Cartesian Therapeutics’s EPS estimate is -0.83.
How many shares outstanding does Cartesian Therapeutics have?
Cartesian Therapeutics has 26,003,607 shares outstanding.
What happened to Cartesian Therapeutics’s price movement after its last earnings report?
Cartesian Therapeutics reported an EPS of -$1.38 in its last earnings report, missing expectations of -$0.847. Following the earnings report the stock price went down -1.565%.
Which hedge fund is a major shareholder of Cartesian Therapeutics?
Currently, no hedge funds are holding shares in RNAC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cartesian Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.67 (380.19% Upside)
$34.67 (380.19% Upside)
Blogger Sentiment
Bullish
RNAC Sentiment 100%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 22.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $205.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.2%
Last 30 Days ▲ 41.5%
Last 30 Days ▲ 41.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-62.53%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-18.15%
Trailing 12-Months
Company Description
Cartesian Therapeutics
Cartesian Therapeutics (RNAC) is a biotechnology company focused on developing innovative RNA-based therapeutics for the treatment of serious diseases. The company operates in the biopharmaceutical sector, leveraging its proprietary RNA platform to create targeted therapies aimed at addressing unmet medical needs in areas such as oncology and autoimmune disorders. Cartesian Therapeutics' core products include engineered RNA medicines designed to enhance the therapeutic potential of traditional treatments and improve patient outcomes.
RNAC Stock 12 Month Forecast
Average Price Target
$34.67
▲(380.19% Upside)
Technical Analysis
Puma Biotechnology
―
DBV Technologies SA - American
―
Voyager Therapeutics
―
Atea Pharmaceuticals
―
Vor Biopharma
―
Ownership Overview
61.62% Insiders
11.84% Mutual Funds
6.09% Other Institutional Investors
16.76% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---